CN101663035B - 4-环丙基甲氧基-n-(3，5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途 - Google Patents

4-环丙基甲氧基-n-(3，5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途 Download PDF

Info

Publication number
CN101663035B
CN101663035B CN2008800126498A CN200880012649A CN101663035B CN 101663035 B CN101663035 B CN 101663035B CN 2008800126498 A CN2008800126498 A CN 2008800126498A CN 200880012649 A CN200880012649 A CN 200880012649A CN 101663035 B CN101663035 B CN 101663035B
Authority
CN
China
Prior art keywords
pyridine
dichloro
pyridin
carboxamide
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800126498A
Other languages
English (en)
Chinese (zh)
Other versions
CN101663035A (zh
Inventor
P·德莱-戈耶特
C·德尔戈奇
C·梅内特
G·波翁
C·拉维内特-特里洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN101663035A publication Critical patent/CN101663035A/zh
Application granted granted Critical
Publication of CN101663035B publication Critical patent/CN101663035B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN2008800126498A 2007-04-19 2008-04-16 4-环丙基甲氧基-n-(3，5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途 Expired - Fee Related CN101663035B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
FR0702853 2007-04-19
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (2)

Publication Number Publication Date
CN101663035A CN101663035A (zh) 2010-03-03
CN101663035B true CN101663035B (zh) 2012-06-20

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800126498A Expired - Fee Related CN101663035B (zh) 2007-04-19 2008-04-16 4-环丙基甲氧基-n-(3，5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途

Country Status (33)

Country Link
US (1) US20100130554A1 (https=)
EP (1) EP2146714B1 (https=)
JP (1) JP5386478B2 (https=)
KR (2) KR20150004885A (https=)
CN (1) CN101663035B (https=)
AR (1) AR066108A1 (https=)
AT (1) ATE513548T1 (https=)
AU (1) AU2008257322B2 (https=)
BR (1) BRPI0810444A2 (https=)
CA (1) CA2684174C (https=)
CL (1) CL2008001136A1 (https=)
CY (1) CY1111840T1 (https=)
DK (1) DK2146714T3 (https=)
EA (1) EA019194B1 (https=)
ES (1) ES2367408T3 (https=)
FR (1) FR2915100B1 (https=)
HR (1) HRP20110666T1 (https=)
IL (1) IL201448A (https=)
JO (1) JO2678B1 (https=)
MA (1) MA31367B1 (https=)
ME (1) ME00935B (https=)
MX (1) MX2009011284A (https=)
MY (1) MY148092A (https=)
NZ (1) NZ580482A (https=)
PA (1) PA8776801A1 (https=)
PL (1) PL2146714T3 (https=)
PT (1) PT2146714E (https=)
RS (1) RS51869B (https=)
SI (1) SI2146714T1 (https=)
TW (1) TWI439269B (https=)
UY (1) UY31035A1 (https=)
WO (1) WO2008145841A1 (https=)
ZA (1) ZA200907251B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955808A (zh) * 2012-11-28 2015-09-30 赛诺菲 4-(环丙基甲氧基)-n-(3,5-二氯-1-氧化吡啶-4-基)-5-甲氧基吡啶-2-甲酰胺的晶型的制备方法以及晶型
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
US20250120957A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004045A1 (en) * 1993-07-28 1995-02-09 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
WO2004005258A1 (en) * 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
JP2005506286A (ja) * 2001-03-02 2005-03-03 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリック−ａｍｐ関連疾患の治療を目的としたメラノコルチン受容体アゴニストおよびホスホジエステラーゼ阻害剤の併用投与
US6911464B2 (en) * 2003-03-12 2005-06-28 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004045A1 (en) * 1993-07-28 1995-02-09 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
WO2004005258A1 (en) * 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors

Also Published As

Publication number Publication date
MA31367B1 (fr) 2010-05-03
PL2146714T3 (pl) 2011-10-31
BRPI0810444A2 (pt) 2016-05-31
DK2146714T3 (da) 2011-10-10
CY1111840T1 (el) 2015-10-07
FR2915100B1 (fr) 2009-06-05
KR20090130059A (ko) 2009-12-17
ATE513548T1 (de) 2011-07-15
PA8776801A1 (es) 2008-11-19
ME00935B (me) 2012-06-20
TW200911247A (en) 2009-03-16
CA2684174A1 (fr) 2008-12-04
ES2367408T3 (es) 2011-11-03
IL201448A (en) 2014-08-31
CA2684174C (fr) 2014-02-25
SI2146714T1 (sl) 2011-10-28
UY31035A1 (es) 2008-11-28
AR066108A1 (es) 2009-07-22
NZ580482A (en) 2011-10-28
KR101503942B1 (ko) 2015-03-18
EA019194B1 (ru) 2014-01-30
CL2008001136A1 (es) 2009-01-16
ZA200907251B (en) 2011-04-28
HK1141725A1 (en) 2010-11-19
JO2678B1 (en) 2013-03-03
WO2008145841A1 (fr) 2008-12-04
AU2008257322B2 (en) 2013-06-13
HRP20110666T1 (hr) 2011-10-31
EA200970970A1 (ru) 2010-02-26
KR20150004885A (ko) 2015-01-13
JP5386478B2 (ja) 2014-01-15
EP2146714A1 (fr) 2010-01-27
FR2915100A1 (fr) 2008-10-24
EP2146714B1 (fr) 2011-06-22
JP2010524906A (ja) 2010-07-22
TWI439269B (zh) 2014-06-01
IL201448A0 (en) 2010-05-31
RS51869B (sr) 2012-02-29
MX2009011284A (es) 2009-11-02
MY148092A (en) 2013-02-28
CN101663035A (zh) 2010-03-03
US20100130554A1 (en) 2010-05-27
PT2146714E (pt) 2011-09-02
AU2008257322A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
CN107847499A (zh) 治疗神经退行性疾病的方法
CN101663035B (zh) 4-环丙基甲氧基-n-(3，5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途
HUP0004813A2 (hu) Készítmények és eljárások légzési rendellenességek kezelésére
CN101674829B (zh) 4-环丙基甲氧基-n-(3,5-二氯代-1-环氧-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺用于治疗脊髓创伤的用途
CN101663036B (zh) 4-环丙基甲氧基-n-(3,5-二氯代-1-氧代-4-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺用于治疗颅脑创伤的用途
CN100372533C (zh) 腹泻为主大肠激惹综合征的治疗制剂
CN117396202A (zh) 给药方案
TW201625253A (zh) 包含ｐｇｄ２拮抗劑之伴隨過敏性疾病之症狀之治療用醫藥
HK1141725B (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament in the treatment of motor disorders related to parkinson's disease
JP2009501205A (ja) 精神病治療用組成物
TW200423972A (en) Tablet having improved solubility
HK1141724B (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1141725

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1141725

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120620

Termination date: 20170416